Detalles de la búsqueda
1.
Antiretrovirals and Weight Change: Weighing the Evidence.
Clin Infect Dis
; 2024 Apr 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-38606799
2.
Long-acting cabotegravir pharmacokinetics with and without oral lead-in for HIV PrEP.
Antimicrob Agents Chemother
; : e0147523, 2024 May 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-38709006
3.
Asian participants' experience in phase 3/3b studies of long-acting cabotegravir and rilpivirine: Efficacy, safety, pharmacokinetic, and virological outcomes through week 96.
HIV Med
; 25(3): 381-390, 2024 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-38147871
4.
Efficacy, safety, and pharmacokinetics by BMI category in Phase 3/3b cabotegravir + rilpivirine long-acting trials.
J Infect Dis
; 2023 Dec 22.
Artículo
en Inglés
| MEDLINE | ID: mdl-38134313
5.
Efficacy and Safety of Switching to the 2-Drug Regimen Dolutegravir/Lamivudine Versus Continuing a 3- or 4-Drug Regimen for Maintaining Virologic Suppression in Adults Living With Human Immunodeficiency Virus 1 (HIV-1): Week 48 Results From the Phase 3, Noninferiority SALSA Randomized Trial.
Clin Infect Dis
; 76(4): 720-729, 2023 02 18.
Artículo
en Inglés
| MEDLINE | ID: mdl-35235656
6.
Expanded Multivariable Models to Assist Patient Selection for Long-Acting Cabotegravir + Rilpivirine Treatment: Clinical Utility of a Combination of Patient, Drug Concentration, and Viral Factors Associated With Virologic Failure.
Clin Infect Dis
; 77(10): 1423-1431, 2023 11 17.
Artículo
en Inglés
| MEDLINE | ID: mdl-37340869
7.
Pregnancy outcomes and pharmacokinetics in pregnant women living with HIV exposed to long-acting cabotegravir and rilpivirine in clinical trials.
HIV Med
; 24(5): 568-579, 2023 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-36411596
8.
An indirect comparison of 144-week efficacy, safety, and tolerability of dolutegravir plus lamivudine and second-generation integrase inhibitor-based, 3-drug, single-tablet regimens in therapy-naive people with HIV-1.
AIDS Res Ther
; 20(1): 17, 2023 03 22.
Artículo
en Inglés
| MEDLINE | ID: mdl-36949442
9.
Efficacy and Safety of Switching to Dolutegravir/Lamivudine Versus Continuing a Tenofovir Alafenamide-Based 3- or 4-Drug Regimen for Maintenance of Virologic Suppression in Adults Living With Human Immunodeficiency Virus Type 1: Results Through Week 144 From the Phase 3, Noninferiority TANGO Randomized Trial.
Clin Infect Dis
; 75(6): 975-986, 2022 09 29.
Artículo
en Inglés
| MEDLINE | ID: mdl-35079789
10.
Efficacy and Safety of Switching to Dolutegravir/Lamivudine Fixed-Dose 2-Drug Regimen vs Continuing a Tenofovir Alafenamide-Based 3- or 4-Drug Regimen for Maintenance of Virologic Suppression in Adults Living With Human Immunodeficiency Virus Type 1: Phase 3, Randomized, Noninferiority TANGO Study.
Clin Infect Dis
; 71(8): 1920-1929, 2020 11 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-31905383
11.
Maternal and foetal outcomes among 4118 women with HIV infection treated with lopinavir/ritonavir during pregnancy: analysis of population-based surveillance data from the national study of HIV in pregnancy and childhood in the United Kingdom and Ireland.
BMC Infect Dis
; 16: 65, 2016 Feb 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-26847625
12.
Barriers to access to care reported by women living with HIV across 27 countries.
AIDS Care
; 27(10): 1220-30, 2015.
Artículo
en Inglés
| MEDLINE | ID: mdl-26168817
13.
Screening for neurocognitive impairment, depression, and anxiety in HIV-infected patients in Western Europe and Canada.
AIDS Care
; 26(12): 1555-61, 2014.
Artículo
en Inglés
| MEDLINE | ID: mdl-25029599
14.
Switching to Dolutegravir/Lamivudine Two-Drug Regimen: Durability and Virologic Outcomes by Age, Sex, and Race in Routine US Clinical Care.
HIV AIDS (Auckl)
; 16: 133-140, 2024.
Artículo
en Inglés
| MEDLINE | ID: mdl-38645753
15.
Cabotegravir + Rilpivirine Long-Acting Injections for HIV Treatment in the US: Real World Data from the OPERA Cohort.
Infect Dis Ther
; 12(12): 2807-2817, 2023 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-37966701
16.
Cardiometabolic Parameters 3 Years After Switch to Dolutegravir/Lamivudine vs Maintenance of Tenofovir Alafenamide-Based Regimens.
Open Forum Infect Dis
; 10(7): ofad359, 2023 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-37520420
17.
Assessing the Virologic Impact of Archived Resistance in the Dolutegravir/Lamivudine 2-Drug Regimen HIV-1 Switch Study TANGO through Week 144.
Viruses
; 15(6)2023 06 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-37376649
18.
Practical dosing guidance for the management of clinician-administered injections of long-acting cabotegravir and rilpivirine.
Ther Adv Infect Dis
; 10: 20499361231214626, 2023.
Artículo
en Inglés
| MEDLINE | ID: mdl-38107552
19.
Sustained Virologic Suppression With Dolutegravir/Lamivudine in a Test-and-Treat Setting Through 48 Weeks.
Open Forum Infect Dis
; 10(3): ofad101, 2023 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-36968959
20.
Efficacy, safety, and tolerability of switching to long-acting cabotegravir plus rilpivirine versus continuing fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide in virologically suppressed adults with HIV, 12-month results (SOLAR): a randomised, open-label, phase 3b, non-inferiority trial.
Lancet HIV
; 10(9): e566-e577, 2023 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-37567205